FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1543703322> ?p ?o ?g. }

• W1543703322 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAOsteosarcoma is one of the primary malignant bone tumors that often occur around the ages of 15 to 20. Despite advances in combined chemotherapy and surgical resection, 30% of osteosarcoma patients still die from tumor or metastasis. Therefore, new treatment strategy is being required. We previously reported that telomerase-specific, replication-competent oncolytic adenovirus (Telomelysin, OBP-301), showed the in vitro and in vivo antitumor effects in human bone and soft tissue sarcoma cells; however OBP-301 could not efficiently prevent bone destruction in an orthotopic xenograft tumor model. Recently, third-generation bisphosphonates, zoledronic acid (ZOL), is widely used to inhibit bone destruction in metastatic bone tumors in the clinical settings. Moreover, ZOL has been shown to induce the antitumor effect synergistically in combination with chemotherapeutic agents in human sarcoma cells. In this study, we investigated the in vitro and in vivo antitumor effects of combination therapy with ZOL and OBP-301 in human osteosarcoma cells. Four human osteosarcoma cell lines, HOS, SaOS-2, U2OS and MNNG/HOS were used. We used XTT assay to examine the antitumor effect of ZOL and OBP-301 individually and combinatory on days 2,3,5. ZOL was treated at concentration of 0 to 10µM, and OBP-301 was infected at multiplicity of infections (MOI) of 0 to 100 plaque forming units (PFU)/cell. Combination index was calculated with the CalcuSyn software (BioSoft) and combined antitumor effect between ZOL and OBP-301 was analyzed. XTT assay revealed that combination treatment of ZOL and OBP-301 showed synergistic and additive effects. To analyze the molecular mechanism in the synergistic effect of ZOL and OBP-301, western blot analysis for apoptosis (PARP) and autophagy (LC3, p62) was performed. Treatment with ZOL induced apoptosis, which was confirmed by the cleavage of PARP, and OBP-301infection induced both apoptosis and autophagy, which is confirmed by conversion of LC3- I to LC3- II and p62 downregulation. Combination treatment showed increased apoptotic cell death in all human osteosarcoma cells. Moreover, in vivo antitumor effect of combination therapy was investigated in an orthotopic xenograft tumor model, in which MNNG/HOS cells (2×106 cells per site) were inoculated into the left tibias of female athymic nude mice. ZOL and OBP-301 were injected subcutaneously and intratumorally, respectively, for three times every week. Tumor volume was measured once a week and bone destruction status was analyzed using 3D-CT imaging system at final assessment. Combination treatment showed increased antitumor effect and efficiently prevented bone destruction compared to monotherapy in an orthotopic xenograft MNNG/HOS tumor model. These results suggest that combination treatment of ZOL and OBP-301 is a promising antitumor strategy for improvement of clinical outcome in patients with osteosarcomas.Citation Format: Yasuaki Yamakawa, Joe Hasei, Hiroshi Tazawa, Toshinori Omori, Shuhei Osaki, Tsuyoshi Sasaki, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Toshifumi Ozaki, Toshiyoshi Fujiwara. Combination therapy of telomerase-specific oncolytic adenovirus and zoledronic acid in human osteosarcoma cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 725. doi:10.1158/1538-7445.AM2014-725" @default.
• W1543703322 created "2016-06-24" @default.
• W1543703322 creator A5015421086 @default.
• W1543703322 creator A5018715608 @default.
• W1543703322 creator A5020130249 @default.
• W1543703322 creator A5024634262 @default.
• W1543703322 creator A5029076256 @default.
• W1543703322 creator A5058700697 @default.
• W1543703322 creator A5063559482 @default.
• W1543703322 creator A5065384314 @default.
• W1543703322 creator A5089374451 @default.
• W1543703322 date "2014-09-30" @default.
• W1543703322 modified "2023-09-26" @default.
• W1543703322 title "Abstract 725: Combination therapy of telomerase-specific oncolytic adenovirus and zoledronic acid in human osteosarcoma cells" @default.
• W1543703322 doi "https://doi.org/10.1158/1538-7445.am2014-725" @default.
• W1543703322 hasPublicationYear "2014" @default.
• W1543703322 type Work @default.
• W1543703322 sameAs 1543703322 @default.
• W1543703322 citedByCount "0" @default.
• W1543703322 crossrefType "proceedings-article" @default.
• W1543703322 hasAuthorship W1543703322A5015421086 @default.
• W1543703322 hasAuthorship W1543703322A5018715608 @default.
• W1543703322 hasAuthorship W1543703322A5020130249 @default.
• W1543703322 hasAuthorship W1543703322A5024634262 @default.
• W1543703322 hasAuthorship W1543703322A5029076256 @default.
• W1543703322 hasAuthorship W1543703322A5058700697 @default.
• W1543703322 hasAuthorship W1543703322A5063559482 @default.
• W1543703322 hasAuthorship W1543703322A5065384314 @default.
• W1543703322 hasAuthorship W1543703322A5089374451 @default.
• W1543703322 hasConcept C104317684 @default.
• W1543703322 hasConcept C142724271 @default.
• W1543703322 hasConcept C143998085 @default.
• W1543703322 hasConcept C150903083 @default.
• W1543703322 hasConcept C185592680 @default.
• W1543703322 hasConcept C207001950 @default.
• W1543703322 hasConcept C2776326535 @default.
• W1543703322 hasConcept C2777283488 @default.
• W1543703322 hasConcept C2777760704 @default.
• W1543703322 hasConcept C2778256501 @default.
• W1543703322 hasConcept C3020616263 @default.
• W1543703322 hasConcept C502942594 @default.
• W1543703322 hasConcept C54355233 @default.
• W1543703322 hasConcept C55493867 @default.
• W1543703322 hasConcept C71924100 @default.
• W1543703322 hasConcept C81885089 @default.
• W1543703322 hasConcept C82210918 @default.
• W1543703322 hasConcept C86803240 @default.
• W1543703322 hasConcept C94581717 @default.
• W1543703322 hasConceptScore W1543703322C104317684 @default.
• W1543703322 hasConceptScore W1543703322C142724271 @default.
• W1543703322 hasConceptScore W1543703322C143998085 @default.
• W1543703322 hasConceptScore W1543703322C150903083 @default.
• W1543703322 hasConceptScore W1543703322C185592680 @default.
• W1543703322 hasConceptScore W1543703322C207001950 @default.
• W1543703322 hasConceptScore W1543703322C2776326535 @default.
• W1543703322 hasConceptScore W1543703322C2777283488 @default.
• W1543703322 hasConceptScore W1543703322C2777760704 @default.
• W1543703322 hasConceptScore W1543703322C2778256501 @default.
• W1543703322 hasConceptScore W1543703322C3020616263 @default.
• W1543703322 hasConceptScore W1543703322C502942594 @default.
• W1543703322 hasConceptScore W1543703322C54355233 @default.
• W1543703322 hasConceptScore W1543703322C55493867 @default.
• W1543703322 hasConceptScore W1543703322C71924100 @default.
• W1543703322 hasConceptScore W1543703322C81885089 @default.
• W1543703322 hasConceptScore W1543703322C82210918 @default.
• W1543703322 hasConceptScore W1543703322C86803240 @default.
• W1543703322 hasConceptScore W1543703322C94581717 @default.
• W1543703322 hasLocation W15437033221 @default.
• W1543703322 hasOpenAccess W1543703322 @default.
• W1543703322 hasPrimaryLocation W15437033221 @default.
• W1543703322 hasRelatedWork W1904301668 @default.
• W1543703322 hasRelatedWork W1972355364 @default.
• W1543703322 hasRelatedWork W1976524741 @default.
• W1543703322 hasRelatedWork W1979847411 @default.
• W1543703322 hasRelatedWork W2026840205 @default.
• W1543703322 hasRelatedWork W2040857439 @default.
• W1543703322 hasRelatedWork W2055709184 @default.
• W1543703322 hasRelatedWork W2058321884 @default.
• W1543703322 hasRelatedWork W2063144211 @default.
• W1543703322 hasRelatedWork W2079712521 @default.
• W1543703322 hasRelatedWork W2142312984 @default.
• W1543703322 hasRelatedWork W2215436068 @default.
• W1543703322 hasRelatedWork W2487423906 @default.
• W1543703322 hasRelatedWork W2529690380 @default.
• W1543703322 hasRelatedWork W2733256002 @default.
• W1543703322 hasRelatedWork W2885603550 @default.
• W1543703322 hasRelatedWork W2887014152 @default.
• W1543703322 hasRelatedWork W2950247171 @default.
• W1543703322 hasRelatedWork W3083661547 @default.
• W1543703322 hasRelatedWork W3098746388 @default.
• W1543703322 isParatext "false" @default.
• W1543703322 isRetracted "false" @default.
• W1543703322 magId "1543703322" @default.
• W1543703322 workType "article" @default.